Navigation Links
Northwest Biotherapeutics Addresses Recent Market Activity
Date:3/16/2011

BETHESDA, Md., March 16, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO).  Taking note of the recent unusual activity in the Company's stock,  Northwest Biotherapeutics (NWBT) commented today that it is not aware of any basis relating to the Company or its products or programs. 

The Company is continuing to move forward with the trial-related activities for its large, 240-patient clinical trial for GBM brain cancer.  The patients treated with NWBT's DCVax treatment in the prior clinical trials have shown strikingly positive results in the ongoing long-term follow-up after those trials.  The Company has developed program activities outside the US to complement its program activities in the US.  The Company believes that the recent unusual activity in its stock does not reflect the fundamentals of the Company.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis.  The Company is developing dendritic cell-based vaccines.  The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal form of brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.    

For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.    


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Northwestern chemists take gold, mass-produce Beijing Olympic logo
2. Northwest Secures US$1.0 Million Debt Financing
3. Northwest Secures US$1.65 Million Debt Financing
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
6. Northwest Biotherapeutics Secures $700,000 Equity Financing
7. Sirius Genomics to Present at Invest Northwest Conference
8. Oncothyreon to present at Invest Northwest 2009
9. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
11. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... May 18, 2017 , ... When James Sherley, was notified earlier this year that his company ... the Year 2017 by The Silicon Review , he was not surprised as others ... Asymmetrex’s value, but this recognition by Silicon Valley was particularly meaningful. Our selection ...
(Date:5/16/2017)... ... May 16, 2017 , ... Cynvenio Biosystems, ... its ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of ... designed to quickly and accurately identify tumor-related genetic mutations that can be treated ...
(Date:5/15/2017)... ... 2017 , ... Tunnell Consulting announced that Julia O’Neill, principal and ... Specifications in Process Validation,” at the Process Validation Summit 2017, May 18 and ... from the pharmaceutical and biotech industries to explore processes, strategies and new approaches to ...
(Date:5/15/2017)... ARMONK, N.Y. , May 15, 2017  IBM ... "lab-on-a-chip" technology that can stretch double-stranded DNA molecules ... may indicate disease. This technology complements ... which separates bioparticles, such as exosomes and which ... nanochannel technology, which uses an array of diamond ...
Breaking Biology Technology:
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
Breaking Biology News(10 mins):